Arcus Biosciences (RCUS) Misses Q4 EPS by 6c

Arcus Biosciences (NYSE: RCUS) reported Q4 EPS of ($1.08), $0.06 worse than the analyst estimate of ($1.02). Revenue for the quarter came in at $31 million versus the consensus estimate of $29.03 million.

For earnings history and earnings-related data on Arcus Biosciences (RCUS) click here.

You May Also Be Interested In

• ​Trump said he was unaware of his earnings from crypto
• SAS CEO van der Werff emerges as frontrunner for Air Canada top job - Bloomberg
• MotorK names Roy Toren to board as Helen Protopapas resigns